Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia.

Bruzzone B, Di Biagio A, Sticchi L, Barresi R, Saladini F, Icardi G, Setti M.

Antimicrob Agents Chemother. 2014 Dec;58(12):7620-1. doi: 10.1128/AAC.03771-14. No abstract available.

2.

Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.

Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM.

J Infect Dis. 2010 May 1;201(9):1303-7. doi: 10.1086/651618.

PMID:
20350161
3.

Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B.

Antimicrob Agents Chemother. 2014 Jul;58(7):3585-98. doi: 10.1128/AAC.00076-14. Epub 2014 Apr 14.

4.

Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.

Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, Hatano H.

Antimicrob Agents Chemother. 2012 Nov;56(11):5998-6000. doi: 10.1128/AAC.01217-12. Epub 2012 Aug 13.

5.

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.

Zaccarelli M, Lorenzini P, Tozzi V, Forbici F, Ceccherini-Silberstein F, Gori C, D'Arrigo R, Trotta MP, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of the HIV Genotype Resistance Test (GRT) at the National Institute for Infectious Diseases "Lazzaro Spallanzani".

Infection. 2009 Jun;37(3):203-9. doi: 10.1007/s15010-008-8142-8. Epub 2009 Mar 9.

PMID:
19274429
6.

Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?

Frenkel LM, Mullins JI.

N Engl J Med. 2001 Feb 15;344(7):520-2. No abstract available.

PMID:
11172196
7.

[Do not let low-level viremia occur in patients treated by antiretrovirals].

Groupe bibliographique de la SPILF, Le Moal G.

Med Mal Infect. 2014 Feb;44(2):83-4. French. No abstract available.

PMID:
24738140
8.

[Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].

Parra-Ruiz J, Alvarez M, Chueca N, Peña A, Pasquau J, López-Ruz MA, Maroto Mdel C, Hernández-Quero J, García F.

Enferm Infecc Microbiol Clin. 2009 Feb;27(2):75-80. doi: 10.1016/j.eimc.2008.02.007. Epub 2009 Feb 13. Spanish.

PMID:
19254638
9.

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.

Fialaire P, Payan C, Vitour D, Chennebault JM, Loison J, Pichard E, Lunel F.

J Infect Dis. 1999 Aug;180(2):574-5. No abstract available.

PMID:
10395889
10.

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ; AIDS Clinical Trials Group A5244 team.

PLoS Med. 2010 Aug 10;7(8). pii: e1000321. doi: 10.1371/journal.pmed.1000321.

11.

Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia.

McConnell MJ, Mier-Mota J, Flor-Parra F, Martinez-Fernandez FJ, Lopez-Cortes LF, Viciana P, Fernandez-Cuenca F, Perez-Romero P.

J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):446-9. doi: 10.1097/QAI.0b013e3182364513.

PMID:
21963935
12.

Selected topics from the 10th Conference on Retroviruses and Opportunistic Infections.

Dybul M.

HIV Clin Trials. 2003 Jul-Aug;4(4):282-6. No abstract available.

PMID:
12916014
13.

[HIV infection: DuPont Pharma presents the results of its antiretroviral agent].

[No authors listed]

Allerg Immunol (Paris). 1998 Apr;30(4):123-4. French. No abstract available.

PMID:
9631694
14.

Potential implication of residual viremia in patients on effective antiretroviral therapy.

Sahu GK.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):25-35. doi: 10.1089/AID.2014.0194. Review.

15.

Clearance of cytomegalovirus viremia after initiation of highly active antiretroviral therapy.

Boivin G, LeBlanc RP.

J Infect Dis. 2000 Mar;181(3):1216-8. No abstract available.

PMID:
10720561
16.

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.

El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, Charalambous S, Petzold M, Katzenstein D, Morris L.

AIDS. 2010 Jul 17;24(11):1679-87. doi: 10.1097/QAD.0b013e32833a097b.

17.

[Preventing rebound viremia after ending ART. Long-term control].

Bischoff A.

MMW Fortschr Med. 2014 Jun 12;156 Suppl 1:10. German. No abstract available.

PMID:
25026845
18.

Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction.

Saison J, Tardy JC, Scholtes C, Icard V, Trabaud MA, Perpoint T, Chidiac C, Ecochard R, André P, Ferry T; Lyon HIV Cohort Study.

J Med Virol. 2013 Jun;85(6):953-8. doi: 10.1002/jmv.23553.

PMID:
23588720
19.

Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy.

Zhang S, van Sighem A, Kesselring A, Gras L, Smit C, Prins JM, Kauffmann R, Richter C, de Wolf F, Reiss P.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):265-72. doi: 10.1097/QAI.0b013e318258c651.

PMID:
22531756
20.

Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.

Simonelli C, Zanussi S, Cinelli R, Dal Maso L, Di Gennaro G, D'Andrea M, Nasti G, Spina M, Vaccher E, De Paoli P, Tirelli U.

Clin Infect Dis. 2003 Sep 15;37(6):820-7. Epub 2003 Aug 28.

PMID:
12955644

Supplemental Content

Support Center